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Aneurysm Severity is Increased by 
Combined Mmp-7 Deletion and 
N-cadherin Mimetic (EC4-Fc) Over-
Expression
Cressida A. Lyon, Helen Williams, Rosaria Bianco, Steven J. Simmonds, Bethan A. Brown, 
Kerry S. Wadey, Frank C. T. Smith, Jason L. Johnson  & Sarah J. George  
There is an unmet need for treatments to reduce abdominal aortic aneurysm (AAA) progression. 
Vascular smooth muscle cell (VSMC) apoptosis precipitates AAA formation, whereas VSMC proliferation 
repairs the vessel wall. We previously demonstrated that over-expression of EC4-Fc (truncated 
N-cadherin), or deletion of matrix-metalloproteinase-7 (Mmp-7) reduced VSMC apoptosis in mouse 
atherosclerotic plaques. Additionally, MMP-7 promotes VSMC apoptosis by cleavage of N-cadherin. 
We investigated their combined effect on AAA formation. Increased apoptosis and proliferation 
were observed in human AAA (HAAA) sections compared to normal aortae (HA). This coincided with 
increased MMP-7 activity and reduced N-cadherin protein levels in HAAA sections compared to HA. 
Using a mouse model of aneurysm formation, we showed that the combination of Mmp-7 deletion 
and EC4-Fc overexpression significantly increased AAA severity. Medial apoptosis and proliferation 
were both significantly reduced in these mice compared to control mice. In vitro, MMP-7 inhibition 
and EC4-Fc administration significantly supressed human aortic VSMC apoptosis (via activation of 
PI-3 kinase/Akt signalling) and proliferation. In conclusion, combined Mmp-7 deletion and systemic 
over-expression of EC4-Fc reduced both proliferation and apoptosis. Reduced proliferation-mediated 
repair over-rides any benefit of reduced apoptosis, increasing aneurysm severity. Future studies should 
therefore focus on retarding VSMC apoptosis whilst promoting VSMC proliferation.
Abdominal aortic aneurysms (AAA) are a common and significant cause of premature death in the UK. It is esti-
mated to be the tenth most common cause of mortality and accounts for 2% of all deaths. Difficulty in diagnosing 
potentially lethal aneurysms prior to rupture has led to screening of men over 65 years old for aortic aneurysms 
using ultrasound in the UK. If a large aneurysm of 5.5 cm or larger is diagnosed, surgical intervention is rec-
ommended. However, if the patient is diagnosed with a smaller aneurysm, there is no specific treatment. These 
patients have six monthly scans to monitor the progression of the aneurysm. Approximately 70% of these patients 
require treatment within 5 years due to increased AAA severity1. Therefore, a drug treatment to reduce aneurysm 
progression and rupture would be a major breakthrough.
Aneurysms are characterised by localised structural deterioration of the artery wall, thinning of the medial 
layer and degeneration of the internal elastic lamina. Loss of medial vascular smooth muscle cells (VSMCs) is an 
important contributor to this disease as the VSMCs provide tensile strength to the vessel wall as well as producing 
extracellular matrix. Various lines of evidence suggest that VSMCs in the artery wall undergo apoptosis during 
the development of an aneurysm. Medial VSMC density was significantly reduced, and apoptosis was signifi-
cantly increased in aneurysmal compared to normal human abdominal aorta tissue specimens2. Additionally, 
p53, a mediator of programmed cell death was increased in these diseased vessels2, as were perforin and Fas which 
are also involved in apoptosis3. Data from animal models of aneurysm formation corroborates the contribu-
tion of apoptosis in AAA4,5. Increased apoptosis (detected by TUNEL, caspase-3 activity and histone-associated 
DNA fragmentation) was observed in angiotensin-II (Ang-II) induced aneurysms in the apolipoprotein E null 
(Apoe−/−) mouse model5,6.
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Figure 1. Enhanced apoptosis, proliferation and MMP-7 activity and reduced N-cadherin levels were observed in 
human AAA samples. (a) Representative images of in situ zymography. Green fluorescence indicates gelatinolytic 
activity. Nuclei are blue (DAPI). Scale bar indicates 20 µm. (b) Analysis of in situ zymography, represented as the 
number of green pixels/view to show gelatinolytic activity. EDTA: broad spectrum MMP inhibitor. * indicates a 
significant difference from HAAA control, $ indicates a significant difference from HAAA + MMP-7 inhibitor 
(MMP-7i) (mean + SEM, n = 4, p < 0.05, ANOVA, Student Newman Keuls Post test). (c) MMP-7 fluorescent activity 
assay of tissue lysates from HAAA and HA. * indicates a significant difference from HA (mean + SEM, n = 9, p < 0.05, 
Mann Whitney test). (d) Western blot analysis for N-cadherin and loading control (β-actin) in tissue lysates from 
HAAA and HA. Graph shows full length N-cadherin data. * indicates a significant difference from HA (mean + SEM, 
n = 9, p < 0.05, Mann Whitney test). Image shows a representative blot. The full length Western blot is included as 
Supplementary Figure 1. (e) Representative images of cleaved caspase-3 and α-SMC-actin immunohistochemistry. 
Positive cells are brown, negative nuclei are blue. Arrows indicate some positive cells. Scale bar indicates 20 µm. 
(f) Analysis of cleaved caspase-3 immunohistochemistry. Apoptosis was measured by counting the proportion of 
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It is feasible that promoting VSMC survival may reduce aneurysm formation and progression and have poten-
tial as a therapeutic approach. To date only one direct study has assessed the effect of inhibiting apoptosis on 
aneurysm formation and progression6. Yamanouchi and colleagues demonstrated that a broad spectrum caspase 
inhibitor significantly reduced aneurysm incidence and size in Ang-II infused Apoe−/− mice6. Additionally, var-
ious studies have shown a link between reduced aneurysm formation and attenuated apoptosis and highlighted 
the use of anti-apoptotic strategies for the treatment of aneurysms5,7–9. Although there is clear potential for 
anti-apoptotic strategies to reduce aneurysm formation and progression, clinically useful compounds have not yet 
been identified. VSMC proliferation may also play a major role in the pathobiology of AAA. VSMC proliferation 
is a vitally important mechanism of repairing the damaged vessel wall and has been found to become activated 
after vessel wall dilation and degeneration of the elastic laminae10.
We have identified two strategies that reduce VSMC apoptosis in mouse. Firstly, via the cell-cell adhesion 
protein N-cadherin. The cadherins are a superfamily of transmembrane glycoproteins that mediate homo-
philic, Ca2+-dependent cell-cell contact11–13. We have previously shown that soluble N-cadherin (SNC), and a 
smaller truncation of SNC, called EC4-Fc, significantly increase features of atherosclerotic plaque stability14,15. 
These studies also showed that SNC-Fc and EC4-Fc are able to modulate VSMC proliferation, migration and 
apoptosis14,15.
The second strategy is inhibition of matrix metalloproteinase-7 (MMP-7). Our interest in MMP-7 was first 
piqued by our comparison of the divergent effects of various MMPs on atherosclerotic plaque stability, which 
found that Mmp-7/Apoe double knockout mice had a higher VSMC content, suggestive of increased plaque 
stability16. Our group have since shown that MMP-7 promotes VSMC apoptosis by cleavage of N-cadherin and 
may therefore modulate atherosclerotic plaque development and rupture17. We observed that mouse VSMCs 
deficient in MMP-7 were 44% less susceptible to Fas-L induced apoptosis than wild-type VSMCs17. Additionally, 
broad-spectrum MMP inhibition is known to reduce proliferation by limiting N-cadherin shedding from the cell 
surface18.
The aims of this study were firstly, to investigate the relevance of our target pathways and molecules in human 
AAA (HAAA) samples, secondly to investigate the effects of EC4-Fc over-expression and Mmp-7 deletion on 
AAA development and progression, using the mouse Ang-II induced aneurysm model and thirdly, to study the 
effects of EC4 administration and MMP7 inhibition in vitro.
Results
Enhanced apoptosis, proliferation and MMP-7 activity and reduced N-cadherin levels were 
observed in human AAA samples. MMP-7 activity was analysed by in situ zymography. Significantly 
higher levels of gelatinolytic activity were detected in human AAA (HAAA) samples compared to control human 
healthy aorta (HA) tissues (Fig. 1a,b). When EDTA (a broad spectrum MMP inhibitor) was added, gelatinolytic 
activity was significantly reduced (Fig. 1b), suggesting that the majority of the proteolytic activity was due to 
MMPs. A MMP-7 selective inhibitor also significantly reduced gelatinolytic activity (Fig. 1b), suggesting that 
the observed activity in HAAA tissue was at least in part due to MMP-7. A fluorescent MMP-7 activity assay 
confirmed these findings, demonstrating significantly elevated MMP-7 activity in HAAA biopsies compared to 
HA (Fig. 1c). In line with the proposition that MMP-7 cleaves N-cadherin, western blot analysis of tissue lysates 
showed that protein levels of full length N-cadherin were significantly lower in HAAA compared to HA, whilst 
more N-cadherin fragment was observed in the HAAA samples (Fig. 1d).
Concomitantly, apoptosis, measured by cleaved caspase-3 immunohistochemistry, was significantly higher in 
the HAAA samples compared to the HA samples (Fig. 1e,f). Serial sections subjected to immunohistochemistry 
for α-smooth muscle actin, revealed apoptosis occurred in smooth muscle cell rich areas of the aneurysm wall 
(Fig. 1e). Proliferation, assessed by PCNA immunohistochemistry, was also significantly higher in the HAAA 
samples compared to the HA samples (Fig. 1g,h), perhaps suggestive of repair processes occurring in the aneu-
rysmal samples.
Ang-II induced aneurysm severity in Apoe−/− mice was increased by combined Mmp-7 knock-
out and EC4-Fc over-expression. As expected and in line with our previous study15, the plasma con-
centration of EC4-Fc was increased in mice transfected with HDAd EC4-Fc compared with that of HDAd-Fc 
transfected control mice (data not shown). Importantly, low density lipoprotein levels were comparable between 
the four treatment groups (Mmp-7+/+ Fc: 22 ± 7 mM, Mmp-7+/+ EC4-Fc: 22 ± 6 mM, Mmp-7−/−, Fc: 20 ± 7 mM, 
Mmp-7−/− EC4-Fc: 23 ± 4 mM). Additionally, no adverse effects on mouse behaviour or appearance were 
observed.
Ang-II induced aneurysms were typed according to their severity (Fig. 2a, more detail in methods). Our 
analysis showed that whilst deletion of Mmp-7 or increased plasma levels of EC4-Fc on their own had no effect 
on aneurysm severity, in combination, aneurysm severity was significantly increased (type 4: ruptured) (Fig. 2b). 
This can be seen macroscopically in the representative photographs in Fig. 2b.
We observed that there was a significant reduction in proliferation (PCNA and Ki67) with both single treat-
ments and the combined treatment (Fig. 3a). There was also a significant reduction in apoptosis (cleaved PARP 
positive cells. * indicates a significant difference from HA (mean + SEM, n = 8, p < 0.05, t test). (g) Representative 
images of PCNA immunohistochemistry. Positive cells are brown, negative nuclei are blue. Arrows indicate some 
positive cells. Scale bar indicates 20 µm. (h) Analysis of PCNA immunohistochemistry. Proliferation was measured by 
counting the proportion of positive cells. * indicates a significant difference from HA (mean + SEM, n = 8, p < 0.05, 
Students t test).
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(cPARP) and cleaved caspase-3) with Mmp-7 deletion and the combined treatments, but not with EC4 alone 
(Fig. 3b). There were no significant differences in any of the other parameters measured, including smooth muscle 
cell and macrophage content, cell density, as well as the cellular senescence marker p16 (Table 1, representative 
images are shown in Supplementary Figure 2).
EC4-Fc and MMP-7 inhibitor reduced proliferation and apoptosis of human aortic 
SMCs. To investigate the potential mechanism of action we firstly examined the effect of EC4-Fc and 
MMP-7 inhibition on primary human aortic smooth muscle cell (HASMC) apoptosis, proliferation and 
migration, using in vitro analyses. Both treatments significantly reduced proliferation induced with bFGF 
and PDGF (Fig. 4a) and 10% FCS (data not shown). EC4-Fc and MMP-7 inhibitor also reduced apoptosis 
induced with Fas-L in these cells, and had an additive effect on apoptosis (Fig. 4b), suggesting increased effi-
cacy when used in combination. There was however no effect of EC4-Fc and MMP-7 inhibition on HASMC 
migration (data not shown).
We investigated whether the pro-survival Akt signalling pathway was involved in the observed anti-apoptotic 
effects using specific inhibitors of Akt and PI3-kinase, and observed that the anti-apoptotic effects were ablated 
by inhibitors of either Akt or PI3-kinase (Fig. 4c).
Figure 2. Ang-II induced aneurysm severity in Apoe−/− mice was increased by combined Mmp-7 deletion and 
EC4-Fc over-expression. (a) Elastin van Gieson staining of aneurysms to show the AAA typing system used to 
rate the severity of the aneurysm. 0: Normal, 1: Dilated, 2: Dilated with atherosclerosis and/or 2 or less elastic 
lamina breaks, 3: Dilated with atherosclerosis and/or 3 or more elastic lamina breaks, 4: Ruptured. Scale bars 
indicate 500 µm. (b) Representative images of the Elastin Van Gieson (EVG) staining, scale bars indicate 500 µm. 
Graph shows the percentage of mice with type 4 aneurysms, typed from the EVG stained sections. * indicates 
a significant difference from WT Fc (n = 17–19, p < 0.05, Fisher’s exact test). Representative macroscopic 
photographs of the abdominal aortae prior to histological analysis.
www.nature.com/scientificreports/
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Figure 3. Combined Mmp-7 deletion and EC4-Fc over-expression resulted in reduced vessel wall proliferation 
and apoptosis in Ang-II induced abdominal aortic aneurysms in Apoe−/− mice. (a) Representative images of 
proliferation markers: PCNA and Ki67 immunohistochemistry in the mouse abdominal aortae. Positive cells 
are brown, negative nuclei are blue. Arrows indicate some positive cells. Scale bar indicates 20 µm. Small panel 
(left-handside) shows high power of Ki67 immunohistochemistry with two positive (brown cells). Analysis 
of immunohistochemistry is shown in the graphs. Proliferation was measured by counting the proportion 
of positive cells. * indicates a significant difference from Mmp-7+/+ Fc. (mean + SEM, n = 17–19, p < 0.05, 
ANOVA, Student Newman Keuls Post test). (b) Representative images of apoptosis markers: cleaved PARP 
(cPARP) and cleaved caspase-3 (CC3) immunohistochemistry in the mouse abdominal aortae. For cPARP: 
positive cells are brown, negative nuclei are blue. For CC3: positive cells are green, negative nuclei are blue. 
Arrows indicate some positive cells. Scale bar indicates 20 µm. Analysis of immunohistochemistry is shown 
in the graphs. Apoptosis was measured by counting the proportion of positive cells. * indicates a significant 
difference from Mmp-7+/+ Fc (mean + SEM, n = 17–19, p < 0.05, Student Newman Keuls Post test for cPARP, 
unpaired t test for CC3).
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Discussion
Apoptosis is crucially important in aneurysm development. Therefore, we investigated two therapeutic strategies, 
which we have previously shown to reduce VSMC apoptosis in vitro and in the Apoe−/− mouse model of athero-
sclerosis: EC4-Fc (truncated N-cadherin) over-expression and Mmp-7 deletion. Conversely, VSMC proliferation 
is known to be activated following vessel wall degradation, and to contribute to repair of the damaged blood 
vessel wall.
In this study, we demonstrated that full length N-cadherin protein levels were lower whilst N-cadherin frag-
ment levels were increased and MMP-7 activity was higher in the HAAA compared to HA. Additionally, we 
confirmed that apoptosis was elevated in HAAA compared to HA, as previously reported2. We also showed 
that proliferation was significantly increased in HAAA compared to HA. This confirms previous findings in 
the ascending thoracic aorta, suggesting that proliferation is activated to repair the damaged vessel10. We pro-
posed therefore that MMP-7 activity and associated loss of N-cadherin may be involved in AAA formation and 
progression.
Although increased levels of apoptosis and proliferation have been previously shown in aneurysm samples, 
this study is the first to evidence that N-cadherin protein levels are significantly reduced, and MMP-7 activity 
is significantly increased in human aneurysmal tissue. This is an interesting finding as it suggests an important 
mechanism by which VSMC apoptosis may be induced in these cells. We have previously demonstrated that 
MMP-7 activation occurs after exposure to pro-apoptotic factors in VSMCs and results in cleavage of N-cadherin 
(thus increasing fragment formation), breaking cell-cell contacts and thus promoting apoptosis17, as cell-cell 
contacts are an important survival signal via activation of Akt19. During proliferation, MMP-dependent cleavage 
of N-cadherin results in its shedding from the cell surface, breaking cell-cell contacts and allowing cell division to 
occur18. It appears that this mechanism may be causing proliferation in aneurysmal tissue.
Our in vivo study, using the Ang-II mouse model of aneurysm formation, showed approximately 17% of mice 
infected with control virus developed severe lesions which is similar to that observed in uninfected mice (16.7%, 
data not shown). This incidence of AAA development is lower than other published studies using this model6,8 
which may be due to strain differences, as we have used double knockout mice, variations in the high-fat diet 
purchased or housing differences. Interestingly, combined deletion of Mmp-7 and overexpression of a soluble 
N-cadherin mimic EC4-Fc (a 50 kDa fragment) resulted in more severe aneurysms. These unexpected findings 
prompted us to analyse the aneurysms further. We found that although Mmp-7−/− alone and combined with 
EC4-Fc reduced apoptosis, this coincided with augmented medial proliferation in the abdominal aorta. Following 
the elastic lamina breakage and vessel dilation that occurs during aneurysm development, VSMCs undergo pro-
liferation to repair the damaged area10. Several other studies have also found that factors which reduce VSMC 
proliferation result in increased aneurysm severity, for example, Emeto et al. suggest that an anti-proliferative 
factor, urocortin-2, is associated with AAA20, or Luo et al., who found that aberrant expression of microRNA-9 
increases intracranial aneurysm development by reducing proliferation21. Together these studies and our data 
suggest a clear association between reduced VSMC proliferation and severe aneurysm formation. We suggest 
that increased plasma levels of EC4-Fc and Mmp-7−/− prevent the essential repair mechanism of the VSMCs in 
the AAA, thus, increasing the severity and likelihood of rupture. This lack of proliferation appears to be more 
important to aneurysm severity than the reduction in apoptosis caused by our treatments.
To corroborate the in vivo data, we performed in vitro experiments which showed that both singly and in 
combination, EC4-Fc and an MMP-7 inhibitor reduced human aortic SMC apoptosis and proliferation. Addition 
of the PI-3 kinase inhibitor and the Akt inhibitor ablated the anti-apoptotic effects of EC4-Fc and the MMP-7 
inhibitor, implying that the two treatments separately and in combination inhibit apoptosis through the PI-3 
kinase/Akt signalling pathway. However, further analyses would be required to directly demonstrate the signal-
ling pathways responsible for the anti-apoptotic action of EC4-Fc and the MMP-7 inhibitor.
Mmp-7+/+ Fc 
(n = 18)
Mmp-7+/+ EC4-
Fc (n = 17)
Mmp-7−/− Fc 
(n = 17)
Mmp-7−/− EC4-
Fc (n = 19)
Smooth muscle cell content
%: actin 95.9 ± 1.6 92.5 ± 3.3 94.3 ± 1.2 91.2 ± 1.7
%: desmin 77.0 ± 4.4 79.7 ± 3.0 68.0 ± 4.7 81.5 ± 4.4
Macrophage content
%: GSL 0.19 ± 0.07 0.45 ± 0.17 0.41 ± 0.23 0.24 ± 0.12
%: CD68 0.73 ± 0.35 0.61 ± 0.10 0.57 ± 0.15 0.88 ± 0.43
Cellular Senescence 
(%: p16) 4.01 ± 2.04 2.22 ± 0.59 2.19 ± 0.61 3.42 ± 1.07
Cell density (cells/area) 0.66 ± 0.05 0.65 ± 0.07 0.87 ± 0.13 0.57 ± 0.02
Medial area 
(µm² × 1000) 252 ± 77 280 ± 98 117 ± 16 164 ± 43
Lumen diameter (µm) 678 ± 37 677 ± 39 649 ± 38 630 ± 41
Medial thickness (µm) 47.2 ± 2.4 45.4 ± 1.9 43.5 ± 2.4 45.9 ± 2.9
Elastic lamina breaks 
(# broken layers) 2.2 ± 0.4 2.1 ± 0.5 1.9 ± 0.4 2.6 ± 0.5
Table 1. Analysis of mouse abdominal aortae using elastin van Gieson staining and immunohistochemistry for 
actin and GSL.
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From the literature, and our previous research, we predict that the mechanisms by which EC4 and MMP-7 
inhibition reduce proliferation will be independent of one another. Soluble N-cadherin, which contains an FGF-R 
binding domain, can reduce proliferation by preventing the nuclear translocation of the FGF-R22. It is likely 
that EC4-Fc is acting in the same manner. MMP inhibition (by BB-94, TIMP-1 or -2) has been shown to retard 
proliferation by preventing N-cadherin cleavage and subsequent shedding from the cell surface18. Maintenance 
of cell-cell contacts is a well-established anti-proliferative mechanism. Together these data suggest that MMP-7 
inhibition or deletion of Mmp-7 is likely to reduce proliferation by maintaining cell-cell contacts.
In conclusion, this study emphasises the importance of VSMC proliferation in aneurysm repair. It appears 
that maintaining VSMC proliferation is equally important as limiting apoptosis in terms of preventing aneurysm 
progression. Consequently, future studies should focus on the identification of agents that retard VSMC apoptosis 
whilst sparing or even promoting VSMC proliferation. We hope that the results of this study will help to guide 
further research into this important area of study.
Figure 4. EC4-Fc and MMP-7 inhibitor reduced proliferation and apoptosis of human aortic SMCs. (a) Human 
aortic VSMCs were treated with 20ng/mL PDGF + 20ng/mL bFGF to stimulate proliferation for 24 hours with 
BrdU, and 100pM Fc or EC4-Fc and 1% DMSO or 0.1 µM MMP-7 inhibitor, then BrdU incorporation quantified. 
* indicates a significant difference from Fc DMSO (mean + SEM, n = 4, p < 0.05, ANOVA, Student Newman Keuls 
Post test). Representative images of BrdU immunocytochemistry. Arrow heads indicate some positive cells, in 
brown. Nuclei are shown in blue. Scale bar indicates 25 µm. (b) Human aortic smooth muscle cells were treated 
with 200ng/mL Fas-L for 24 hours to induce apoptosis, in the presence of 100pM Fc or EC4-Fc and 1% DMSO or 
0.1 µM MMP-7 inhibitor. Apoptosis was measured by cleaved caspase-3 (CC3) and the percentage of positive cells 
was counted. * indicates a significant difference from DMSO Fc. # indicates a significant difference from all other 
conditions (mean + SEM, n = 4, p < 0.05, ANOVA, Student Newman Keuls Post test). Representative images of 
cleaved caspase-3 immunocytochemistry. Arrowheads indicate positive cells in green. Nuclei are shown in blue. 
Scale bar indicates 25 µm. (c) Human aortic smooth muscle cells were treated with 200ng/mL Fas-L for 24 hours to 
induce apoptosis, in the presence or absence of 100pM Fc or EC4-Fc and 1% DMSO or 0.1 µM MMP-7 inhibitor 
as well as 10 µM Akt inhbitor or 20 nM PI3-kinase inhibitor (Wortmannin). Apoptosis was measured by cleaved 
caspase-3 (CC3) and the percentage of positive cells was counted. * indicates a significant difference from Control 
Fc (mean + SEM, n = 4, p < 0.05, ANOVA, Student Newman Keuls Post test).
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Methods
Human aortic sample preparation. Samples of human abdominal aortic aneurysm (HAAA) were 
obtained following emergency or planned surgeries to remove large aneurysms. Ethical permission was gained 
for the protocols used in this study from the local research ethics committee (Research Ethics Committee #11/
H0102/3), as well as from the University of Bristol and University Hospital Bristol Review Boards. Patient consent 
was not required for these samples as in accordance with the Human Tissue Act 2004 in UK, this surplus tissue 
was deemed to be waste after surgery which does not require consent for anonymised research purposes. The 
segments of aneurysmal tissue that were received from surgery were heterogeneous in size and some differences 
in composition were noted. On average, the segments of tissue were approximately 1cm–2cm long and 1 cm wide. 
These were then divided into 3 pieces: 1 was formalin fixed for histology, 1 was snap frozen for tissue lysates (west-
ern blots and MMP7 activity assay) and 1 was snap frozen for frozen sections (in situ zymography). The segment 
for histology was often subdivided as it was still large for processing. From these, we excluded acellular areas, 
selecting cellular areas with inflammation (macrophages) and evidence of overlying atherosclerosis to achieve a 
greater homogeneity between samples.
Samples of control undiseased human aorta (HA) were obtained from the hearts donated to the Bristol 
Coronary BioBank (Research Ethics Committee #08/HO107/48). Consent was obtained from the patient or their 
family. All human samples were completely anonymous. These samples were formalin fixed and paraffin embed-
ded, or snap frozen. All methods were performed in accordance with the relevant guidelines and regulations.
In situ zymography. In situ zymography was performed as described previously23. Briefly, 8–10 micron 
sections of frozen tissue samples were cut in optimal cutting temperature compound (OCT). Sections were incu-
bated overnight in the dark at room temperature with a 20 µg/mL solution of DQ-gelatin (D-12054 Molecular 
Probes) diluted in zymogram development buffer (161-0766 BioRad), in the presence or absence of 1 µM MMP-7 
inhibitor or 20 mM EDTA. After 24 hours, slides were washed in PBS and mounted in Prolong Gold with DAPI 
(Life Technologies). Gelatinase activity was visualised as green fluorescence.
MMP activity assay. Tissue samples were lysed in MMP lysis buffer (50 mM Tris pH7.4, 1 mM monothi-
olglycerol) and MMP-7 activity quantified using a fluorimetric assay. Samples were incubated with 0.14 mg/mL 
DQ-gelatin fluorescent substrate with and without 0.5 µM MMP-7 inhibitor (444264, Calbiochem) and fluores-
cence read using a Fluorostar Optima fluorimeter every 30 minutes from 5 hours until peak fluorescence was 
achieved. MMP-7 activity (i.e. that inhibited by the MMP-7 inhibitor) was compared with that detected from a 
standard curve of human active recombinant MMP-7 (444270 Calbiochem).
Western blotting. SDS lysed tissue extracts were subjected to Western blotting as described previously18. 
Blots were incubated overnight at 4 °C with primary antibodies diluted in Starting block (Pierce, Chester, UK). 
Antibodies were used at the following concentrations: N-cadherin (BD Biosciences: 610920, 1:2,500), β-actin 
(Sigma, A5316, 1:10,000). Bound antibodies were detected by rabbit anti-mouse or swine anti-rabbit horseradish 
peroxidase conjugated antibodies (Dako) and enhanced chemiluminescence (Amersham International).
Immunohistochemistry (human specimens). Proliferating and apoptotic cells were identified by immu-
nohistochemistry for proliferating cell nuclear antigen (PCNA, abcam 18197, 1 µg/ml) and cleaved caspase-3 
(CC3, R&D Systems, AF835, 10 µg/ml), as described previously14,24. Smooth muscle cells were identified by 
immunohistochemistry for alpha smooth muscle cell actin (Sigma, A2547, 3.1 µg/ml). Non-immune immu-
noglobulin controls were performed for all protocols by substituting the primary antibody with non-immune 
immunoglobulin of the same species and at the same concentration (Supplementary Figure 3).
Helper dependent adenovirus (HDAd) production. Plasmids encoding c-myc tagged Fc and EC4-Fc from 
our previous study15 were cloned into helper dependent adenovirus (HDAd) vectors by Professor Lawrence Chan 
and Kazuhiro Oka at the Baylor College of Medicine, Houston, USA in the same manner as described previously24.
Mouse Ang-II- induced aneurysm model. Mmp-7−/− mice (on a pure C57Bl/6J strain background, 
obtained from Jax Mice) were crossed with Apoe null mice (C57Bl/8J) to obtain male mice deficient for both 
Mmp-7 and Apoe (Mmp-7−/−Apoe−/−). These mice were bred within the Animal Unit of the University of 
Bristol. Housing, care and all procedures were performed in accordance with the guidelines and regulations of 
the University of Bristol and the United Kingdom Home Office (PPL # 30/2911) and this study was approved by 
University of Bristol Review Board. Male 8 week old mice were fed a high-fat rodent diet containing 21% (w/w) 
fat from lard supplemented with 0.15% (w/w) cholesterol (Special Diets Services, Witham, UK) for 4 weeks. Then 
Alzet 2004 osmotic mini-pumps were subcutaneously implanted to deliver Ang-II at 1000 ng/min/kg for 28 days 
to induce aneurysm formation25. Two days prior to implanting the osmotic mini-pumps, the HDAds (2.25 × 108 
viral particles of virus per mouse in 150 μL of PBS) were administered via tail vein injection as previously24, to 
increase plasma levels of EC4-Fc and Fc. Mice were maintained on high-fat for a further 28 days, then terminated, 
abdominal aortas removed and paraffin wax embedded. Histological analysis (Elastin Van Gieson staining) for 
aneurysm size and elastin content and fragmentation were performed.
The four experimental groups were as follows:
Wild type mice transduced with HDAd Fc (Mmp-7+/+ Fc) n = 18
Wild type mice transduced with HDAd EC4-Fc (Mmp-7+/+ EC4-Fc) n = 17
Mmp-7 depleted mice transduced with HDAd Fc (Mmp-7−/− Fc) n = 17
Mmp-7 depleted mice transduced with HDAd EC4-Fc (Mmp-7−/− EC4-Fc) n = 19
www.nature.com/scientificreports/
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Aneurysm scoring system. Aneurysm severity was scored using the following scale (see Fig. 3 for example 
EVG photographs):
0: Normal
1: Dilated
2: Dilated with atherosclerosis and/or 2 or less elastic lamina breaks
3: Dilated with atherosclerosis and/or 3 or more elastic lamina breaks
4: Ruptured
Quantification of plasma EC4-Fc and lipoprotein levels. Plasma samples were taken when the mice 
were terminated, 28 days after HDAd administration and levels of EC4-Fc were analysed by Western blotting. 
To detect EC4-Fc, immunoprecipitation of c-myc tag using the ProFound c-myc tag IP/co-IP kit was performed 
(Fisher Scientific, Loughborough, UK). Blots were detected with c-myc tag antibody (Cell Signalling, Danvers, 
USA), and a swine anti-rabbit secondary antibody (Dako, High Wycombe, UK). Plasma lipid profiles were ana-
lysed in terminal plasma samples as previously described26.
Immunohistochemistry (mouse specimens). VSMCs, macrophages and proliferating cells were iden-
tified by immunohistochemistry for α-smooth muscle cell actin (Sigma, A2547, 3.1 µg/ml)and desmin (R&D 
Systems, AF3844, 5 µg/ml), Griffonia Simplicifolia Lectin-1 (GSL, Vector, B-1205, 2.5 µg/ml) and CD68 (LSBio, 
LS-C343891, 1 µg/ml) and proliferating cell nuclear antigen (PCNA, abcam 18197, 1 µg/ml) and Ki67 (DAKO, 
M7249, 3.8 ug/ml), respectively, as described previously14,24. Cleaved caspase-3 (R&D Systems, AF835, 10 µg/ml) 
as described previously14,24) and cleaved PARP (abcam, ab32064, 4.8 µg/ml) were used to identify apoptotic cells. 
Briefly, antigen retrieval was performed by boiling in citrate buffer, blocking step was with 5% goat serum, the 
primary antibody for cleaved PARP was added and incubated overnight at 4 °C. Biotinylated anti-rabbit second-
ary antibody was utilised, followed by Extravidin-HRP and DAB (3,3′-diaminobenzidine). Nuclei were counter-
stained with haematoxylin. Immunohistochemistry for a marker of cellular senescence, p16 (Santa Cruz, sc-1661, 
2 µg/ml) was performed as described previously27. Non-immune immunoglobulin controls were performed for 
all protocols by substituting the primary antibody with non-immune immunoglobulin of the same species and at 
the same concentration (Supplementary Figure 3).
Cell culture. Human aortic VSMCs at passage 4–8 were propagated from explants using our previously 
described method18. Ethical permission was gained for this study from the local research ethics committee 
(Research Ethics Committee #11/H0102/3) as well as approval from the University of Bristol and NHS Review 
Boards. Consent was obtained from the patient or patient’s family for the human aortic tissue. Each experiment 
was carried out with aortic VSMCs from at least 3 different patients. All methods were performed in accordance 
with the relevant guidelines and regulations.
Purification of Fc and EC4-Fc proteins. CHO cells were transduced with 50 pfu/cell of RAd Fc or RAd 
EC4-Fc as described previously14. The conditioned media was collected at 66 and 138 hours after transduction/
transfection. The conditioned media was pooled and protein purification was achieved with protein A columns 
(Amersham Biosciences). The protein concentration was determined using the Bradford Protein assay (Sigma) 
and compared by Western blotting.
Apoptosis assay. To enable the detection of apoptotic cells by immunocytochemistry, cells were grown on 
glass coverslips. Human VSMC apoptosis was induced by culturing in serum-free media with 200 ng/mL Fas-L 
for 24 hours. Cells were supplemented with 100 pM Fc or EC4-Fc as well as 0.1 µM MMP-7 inhibitor (444264, 
Calbiochem) to assess their anti-apoptotic effects. In some experiments VSMCs were also treated with 20 nM 
Wortmannin (Calbiochem) or 10 μM Akt inhibitor (Calbiochem) to inhibit PI-3K and Akt signalling, respec-
tively. Apoptosis was assessed by cleaved caspase-3 immunocytochemistry (R&D Systems, AF835, 1 µg/ml) as 
previously19.
Proliferation assay. Proliferation of aortic VSMCs in the presence of 20 ng/mL platelet-derived growth 
factor-BB (PDGF-BB) and 20 ng/mL basic fibroblast growth factor (bFGF) was assessed by performing immuno-
cytochemistry for incorporated bromodeoxyuridine (BrdU, Sigma, B8434, 8.6 μg/ml) as previously28,29.
Migration assay. The migration of VSMCs was determined by plating 4 × 104 cells in 24 well plates with 10% 
(v/v) foetal calf serum and assessed by a scratch wound assay, as described previously22.
Statistics. Results are expressed as mean ± SEM. All data was checked for normal distribution, normally dis-
tributed data were analysed by student t-test for comparison of two groups, non-normally distributed data were 
analysed by Mann Whitney for comparison of two groups and two-way ANOVA with Student Newman Keuls 
post-test was used for multiple comparisons with more than two groups of normally distributed data. Fisher’s 
exact test was used for analysis of severity of AAA data. A significant difference was accepted when p < 0.05.
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